Hwajung et al. [33] showed that the percentage of CD133+EpCAM+ cancer stem cell (CSC) populations was significantly increased in hepatocellular carcinoma cell lines Huh7 and HEP3B, when treated with mTOR inhibitors, sirolimus and everolimus. Here, EPCAM is linked to hepatocellular carcinoma.